Compare OFAL & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFAL | ARTL |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 1.4M |
| IPO Year | 2026 | 2014 |
| Metric | OFAL | ARTL |
|---|---|---|
| Price | $2.13 | $1.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 310.9K | 27.2K |
| Earning Date | 07-14-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $716,885.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 254.88 | N/A |
| 52 Week Low | $0.01 | $0.52 |
| 52 Week High | $3.86 | $179.19 |
| Indicator | OFAL | ARTL |
|---|---|---|
| Relative Strength Index (RSI) | 72.23 | 26.43 |
| Support Level | $0.06 | $0.52 |
| Resistance Level | N/A | $6.81 |
| Average True Range (ATR) | 0.40 | 0.25 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 57.25 | 0.00 |
OFA Group provides interior design, fit-out, project management and application services in Hong Kong for commercial and residential buildings. Its interior design services include consultation, conceptualized designs, layout plans, detailed design drawings and advice on budgetary considerations, space utilization, materials, fittings, furniture, appliances and other items. Its fit-out services include the installation of protective materials, partition walls, windows, decorative fittings, furniture, fixtures, plumbing systems, switches, power outlets, telephone wiring, computer outlet covers and other electrical and wiring works. The Group is transitioning from a project-based model to a subscription-based model for AI tools, real estate development and senior care infrastructure.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.